A trial fibrillation (AF) is the most frequent cardiac arrhythmia in the clinical setting. It is associated with shorter action potential duration (APD) and effective refractory period and a loss of rate-dependent APD adaptation that involve concomitant alterations in ion current activity. 1, 2 Ion channel remodeling in patients with chronic AF (cAF) includes decreased density of L-type Ca 2ϩ currents (I Ca,L ) and increased amplitude of the background inward rectifier K ϩ current I K1 . [3] [4] [5] [6] [7] [8] The changes in atrial electrical properties (electrical remodeling) promote induction of AF and the tendency of the arrhythmia to be sustained. 1 The autonomic nervous system may also contribute to initiation and persistence of AF. Vagal stimulation reduces atrial APD and effective refractory period and increases dispersion of atrial repolarization. 9 This creates an arrhythmogenic substrate for reentry of the excitation wavefront, which promotes the duration of the AF episodes. 1 Although it is generally accepted that vagal nerve activation contributes to initiation of AF, its precise role in cAF and the underlying molecular mechanisms are currently unknown.
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Vagally released acetylcholine (ACh) stimulates muscarinic receptors (M-receptors) and activates the atrial AChregulated potassium current I K,ACh . 10 The resulting shortening of APD in response to M-receptor stimulation is mediated by I K,ACh because in knockout mice lacking this channel, M-receptor stimulation did not induce AF. 11 Therefore, increased activity of I K,ACh was expected to contribute to induction or perpetuation of AF. Studies in atrial biopsies from patients with cAF revealed, however, that both expression of the Kir3.1 and Kir3.4 channel subunits and activation of whole-cell I K,ACh in response to M-receptor stimulation were lower in AF than in sinus rhythm (SR). 6, 7, 12, 13 This was interpreted as an adaptation of atrial myocytes to the high beating rate by reducing I K,ACh to counteract the shortening of APD. 2 Reduced M-receptor-mediated activation of I K,ACh in AF compared with SR is associated with higher I K1 amplitude. 3, 4, 6, 7, 14, 15 Although larger amplitude of I K1 during AF is paralleled by increased mRNA and protein levels of the Kir2.1 channel subunit, 6, 15 the molecular basis of increased I K1 remains incompletely understood. One possibility is that I K,ACh or the ATP-regulated inward rectifier I K,ATP , which cannot be distinguished electrophysiologically at the whole-cell level, contributes to background I K1 by developing spontaneous activity. Therefore, throughout the remainder of this report, inward rectifier current in the absence of agonists is called basal current rather than I K1 .
Theoretically, each component of the M-receptor-mediated signal transduction, including I K,ACh , may develop spontaneous activity in the absence of abnormal vagal tone. For instance, dog atrial myocytes possess a constitutively active I K,ACh -like current that develops higher amplitude after 1 week of atrial tachypacing. 16 Hence, constitutively active I K,ACh channels may also exist in atria of AF patients.
The present study tested the hypothesis that increased I K1 in patients with cAF consists of enhanced I K1 and constitutively active I K,ACh current components.
Methods

Human Samples
The study was approved by the local ethics committee of the university (No. EK790799), and each patient gave written informed consent.
Right atrial appendages were obtained from 46 patients with SR and 33 patients with cAF (cAF Ͼ6 months; Table 1 ).
Electrophysiological Recordings
Atrial myocytes were isolated with the use of our previous protocol 17 and were suspended in storage solution (in mmol/L: KCl 20, KH 2 PO 4 10, glucose 10, K-glutamate 70, ␤-hydroxybutyrate 10, taurine 10, EGTA 10, albumin 1, pH 7.4). Membrane currents were measured with standard whole-cell voltage-clamp techniques. ISO-2 software (MFK) was used for whole-cell and single-channel data acquisition and analysis.
For whole-cell measurements, borosilicate glass microelectrodes had tip resistances of 1 to 2 M⍀ when filled with pipette solution (in mmol/L: K-aspartate 100, NaCl 10, KCl 40, Mg-ATP 5, EGTA 2, GTP-Tris 0.1, HEPES 10, pH 7.4). Myocytes were superfused with a solution containing the following (in mmol/L): NaCl 120, KCl 20, MgCl 2 1, CaCl 2 2, glucose 10, HEPES 10, pH 7.4 at 22°C to 24°C. Seal resistances were 4 to 8 G⍀. Series resistance and cell capacitance were compensated. Basal current was measured by applying a depolarizing ramp pulse from Ϫ100 to ϩ40 mV (holding potential Ϫ80 mV; see inset in Figure 1A ). I K,ACh was stimulated with the nonselective M-receptor agonist carbachol (CCh) (2 mol/L) and was identified with the selective bee venom toxin tertiapin. 18 The nature of basal current and I K,ACh as inward rectifier currents was proven in each myocyte by applying Ba 2ϩ (1 mmol/L) at the end of the experiments. The myocytes were superfused with tyrode solution via a peristaltic pump throughout the experiments. Drugs were applied via an additional rapid solution exchange system (ALA Scientific Instruments). During drug-free periods, the rapid solution exchange system supplied tyrode solution only. Data were not corrected for the calculated liquid junction potential (Ϫ12 mV; software JPCalc, version 2.2). To control for variability in myocyte size, the currents are expressed as densities (pA/pF).
Single-channel currents were recorded in cell-attached configuration (Axopatch 200B, Axon Instruments). The bath solution contained the following (in mmol/L): NaCl 120, KCl 20, MgCl 2 1, CaCl 2 2, glucose 10, HEPES 10, pH 7.4 with NaOH. Borosilicate glass microelectrodes were coated with Sylgard (Dow Corning) and had tip resistances of 3 to 8 M⍀ when filled with the pipette solution (in mmol/L: KCl 140, HEPES 10, pH 7.2 with KOH). I K,ACh was activated by including 10 mol/L CCh into the pipette solution; identity of I K,ACh in the absence of CCh application was tested by applying 10 nmol/L tertiapin to the bath solution. 
Molecular Analysis of the G␤3 Gene
Direct activation of I K,ACh is mediated by ␤␥-subunits of G proteins. The G protein ␤ 3 subunit gene (GNB3) contains a C825T poly- Lipid-lowering drugs, n 29 13* CAD indicates coronary artery disease; MVD, mitral valve disease requiring valve replacement; AVD, aortic valve disease requiring valve replacement; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVEDP, left ventricular end-diastolic pressure; LAD, left atrial diameter; IVS, interventricular septum thickness; LVPW, left ventricular posterior wall thickness; ACE, angiotensin-converting enzyme; and AT, angiotensin receptor. *PϽ0.05, values from unpaired Student t test for continuous variables and from 2 test for categorical variables.
morphism, whereby homozygous 825T-allele carriers exhibit larger basal inward rectifier K ϩ current densities possibly because of enhanced signal transduction. 17 To exclude confounding by homozygous 825T-allele carriers, all patients were genotyped for the C825T polymorphism. DNA extraction and genotyping were performed in a blinded manner as described. 7 In this report the patient sample includes homozygous and heterozygous C825-allele carriers only.
Statistical Analysis
Throughout this report, n refers to the number of myocytes/patients, unless otherwise stated. For quantitative comparisons, average values were calculated from multiple data obtained from 1 patient. Because the number of cells investigated varied widely in each patient (unbalanced observations), we calculated means from average values for each patient.
One-way ANOVAs were applied to determine the sources of K ϩ current variation (SPSS version 12.0). Independent variables were cAF, selected clinical variables, and medication (Table 1) . Differences between group means for continuous data were compared by unpaired Student t test or when patients with SR or cAF were stratified by underlying disease or medication by 1-way ANOVA and post hoc multiple comparisons tests (Bonferroni t test). The concentration-dependent effects of tertiapin on basal and CCh-activated current were evaluated with a mixed linear model (with fixed factors for rhythm status and concentration of tertiapin and random factor for subjects) followed by post hoc Tukey-Kramer t test (SAS version 9.1). To calculate the concentration of tertiapin blocking the CCh-activated I K,ACh by 50% (IC 50 ) in SR and cAF, the concentration-response curve of the mean values was fitted to a 4-parameter logistic function (Prism version 4.0). Frequency data were analyzed with 2 statistics. PϽ0.05 was considered statistically significant.
Results
Amplitudes of basal current and I K,ACh were related to selected clinical variables. Significant differences between the 2 groups were found for hyperlipidemia and left atrial diameter. Patients with cAF more often received digitalis and diuretics, whereas lipid-lowering drugs were more frequently used in those with SR ( Table 1 ). The patients used for the tertiapin studies showed clinical characteristics comparable to those of the other groups. With 1-way ANOVAs, AF was the only predictor of basal current and I K,ACh current density (data not shown).
Basal Current and I K,ACh in Atrial Myocytes of SR and cAF Patients
In voltage-clamped human atrial myocytes, cell capacitances averaged 80.3Ϯ4.7 pF (nϭ136) for SR and 89.6Ϯ4.1 pF (nϭ76) for cAF myocytes (PϽ0.05). Basal current in the absence of agonist ( Figure 1A ) was confirmed to be larger in cAF than in SR (at Ϫ100 mV: Ϫ22.9Ϯ2.1 pA/pF, nϭ76/25 [myocytes/patients] versus Ϫ12.7Ϯ1.0 pA/pF, nϭ136/38; PϽ0.05).
Application of CCh resulted in rapid initial increase (Peak) of I K,ACh amplitude, which was followed by a decrease to a quasi-steady state level (Qss) despite the continuous presence of CCh (desensitization). 10 There was no difference in desensitization of I K,ACh between myocytes from SR and cAF patients ( Figure 1B) , the Peak/Qss ratio of I K,ACh being 0.58Ϯ0.06 (nϭ76/25) for AF versus 0.54Ϯ0.03 (nϭ136/38) for SR (PϭNS). As expected, the CCh-activated Peak-and Qss-I K,ACh currents were smaller in cAF than in SR groups ( Figure 1B, 1C ).
Effects of Tertiapin on Basal Current and I K,ACh
The selective I K,ACh blocker tertiapin 18 was used to discriminate between I K1 and I K,ACh contribution to enhanced basal current in AF. Tertiapin blocks I K,ACh with IC 50 values between 8 and 30 nmol/L without any effect on I K1 up to 1 mol/L. 16, 19, 20 For this set of experiments we applied CCh (2 mol/L) twice with 4 minutes of washing in between (S 1 , S 2 ). S 1 served as internal control, whereas S 2 was measured in the presence of tertiapin or the nonselective M-receptor blocker atropine. Even under control conditions, I K,ACh was lower during S 2 than during S 1 , suggesting incomplete recovery from desensitization (Figure 2A, 2B) . However, the degrees of I K,ACh desensitization were similar in SR and cAF myocytes ( Figure 2C ).
Application of tertiapin (0.1 to 100 nmol/L) during S 2 reduced the S 2 /S 1 ratio in a concentration-dependent manner, with greater potency in cAF than in SR (ϪlogIC 50 : 9.1 for AF versus 8.2 for SR; PϽ0.05; Figure 3A to 3C). In addition, tertiapin concentration-dependently impaired basal current in cAF, yielding a tertiapin-sensitive component of Ϫ6.7Ϯ1.2 pA/pF at 10 nmol/L (nϭ16/5; Figure Figure 3D ), suggesting enhanced I K1 in these patients.
Tertiapin also suppressed a component of basal current in SR; however, this amounted to only Ϫ1.7Ϯ0.5 pA/pF at 10 nmol/L (nϭ24/8). Application of drug-free tyrode solution alone caused a small decrease of basal current by Ϫ1.5Ϯ0.6 pA/pF (nϭ5/4) in SR and Ϫ1.6Ϯ1.2 pA/pF (nϭ4/3) in cAF. Our results suggest constitutively active I K,ACh channels in cAF only ( Figure 3A, 3C) .
The cAF patients involved in the experiments with tertiapin did not have a history of vagally mediated AF. Compared with SR, they had larger left atria and a higher prevalence of diabetes, and they more frequently took diuretics (Table 1) . However, basal currents were similar in cAF patients with and without valvular heart disease (28.7Ϯ4.2 pA/pF, nϭ21/5 versus Ϫ26.2Ϯ4.4 pA/pF, nϭ17/4) or diabetes (27.1Ϯ3.4 pA/pF, nϭ28/7 versus Ϫ29.2Ϯ7.5 pA/pF, nϭ10/2). The same holds true for treatment with diuretics (27.9Ϯ3.5 pA/pF, nϭ24/6 versus Ϫ26.9Ϯ6.2 pA/pF, nϭ14/3). The tertiapin (10 nmol/L)sensitive current component was 6.4Ϯ1.5 pA/pF (nϭ12/3) and 6.3Ϯ1.6 pA/pF (nϭ12/4) in the absence of diuretics and digitalis, respectively, suggesting a lack of drug effects on constitutively active I K,ACh channels in cAF.
Next we excluded the contribution of spontaneously active M-receptors to enhanced basal current in cAF. Atropine (1 mol/L) abolished the CCh-activated I K,ACh in both groups without effect on basal currents. Thus, tertiapin-sensitive constitutive activity of I K,ACh is independent of M-receptors ( Figure 4 ).
Single-Channel Activity of I K1 and I K,ACh in SR and Chronic AF Patients
For a more direct proof of constitutive activity of I K,ACh channels in cAF, we measured single-channel activity in the cell-attached mode. Constitutive activity of I K,ACh was detected in cAF but was minute in SR (channel open probability: cAF, 5.4Ϯ0.8%, nϭ19/9 versus SR, 0.1Ϯ0.01%, nϭ16/9; PϽ0.05; Figure 5A to 5C). Moreover, open probability of I K1 was higher in cAF than in SR (13.4Ϯ0.4%, nϭ19/9 versus 11.4Ϯ0.7%, nϭ16/9; PϽ0.05; Figure 5D ) without changes in other channel characteristics ( Table 2) . Exclusion of cAF patients taking diuretics or digitalis had no impact on constitutive activity of I K,ACh . Open probability of I K,ACh was 6.1Ϯ0.7% (nϭ8/4) and 5.2Ϯ0.5% (nϭ9/4) in the absence of diuretics and digitalis, respectively. Inclusion of 10 mol/L CCh in the pipette solution caused single-channel openings in periodic bursts in all SR and cAF myocytes studied. Amplitudes and open times of constitutively active I K,ACh channels were not different from those of channels activated with CCh ( Table 2) .
Exposure of myocytes from SR patients with tertiapin (10 nmol/L) reduced open probability of CCh-activated I K,ACh (Figure 6A, 6C) , which is in agreement with previous results obtained in rabbit atrial myocytes. 20 Consistent with the reduction of whole-cell basal current shown in Figure 3C , open probability of constitutively active I K,ACh during cAF was lower in the presence of 10 nmol/L tertiapin without concomitant effects on I K1 (Figure 6B,  6D ).
Discussion
In the present study we demonstrate that in addition to enhanced subunit expression, increased open probability of I K1 channels contributes to higher basal inward rectifier K ϩ current in patients with cAF. We provide evidence for involvement of agonist-independent constitutive activity of I K,ACh channels from several observations: (1) the selective I K,ACh inhibitor tertiapin reduced basal current in cAF but not in SR; (2) single-channel measurements demonstrated spontaneous openings of I K,ACh channels in myocytes from cAF patients only; and (3) the open probability of constitutively active single I K,ACh channels during cAF was lower in the presence of tertiapin. Evidence for agonist-independent constitutive activity of I K,ACh was provided by the lack of block of these channels by the M-receptor antagonist atropine. Our results suggest that in cAF the higher basal inward rectifier K ϩ current results from increased expression and open probability of I K1 and constitutively active I K,ACh channels, which may contribute to the perpetuation of the arrhythmia. 
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Comparison With Previous Studies
At the whole-cell level, several studies reported higher amplitude of basal inward rectifier K ϩ current in cAF than in SR patients. 3, 4, 6, 7, 14, 15 Pacing-induced tachycardia in dogs also results in higher I K1 amplitude, 16, 21 suggesting that the increase in I K1 is a consequence of the arrhythmia. Because expression of the corresponding channel subunits at mRNA and protein levels followed the increase in current amplitude, 6, 15 it was concluded that modified channel subunit transcription and/or translation is the only mechanism of increased I K1 during human cAF. Our results at the singlechannel level, however, showed that open probability of I K1 is slightly but significantly higher in cAF than in SR, suggesting that the molecular basis of increased I K1 is more complex and involves not only increased channel subunit expression but also additional modifications of channel regulation. The molecular mechanisms of enhanced open channel probability of I K1 are currently unknown but may involve impaired phosphorylation-dependent regulation. The Kir2.x channel subunits of I K1 possess phosphorylation sites for different kinases, and higher channel subunit phosphorylation results in lower I K1 amplitude. 22, 23 Because cAF is associated with higher activity of the counterbalancing type 1 and type 2A serine/threonine protein phosphatases, 8 it cannot be excluded that the expected stronger channel dephosphorylation contributes to higher I K1 activity in AF. Further studies are needed to identify the molecular mechanisms of modified I K1 regulation in cAF patients. Consistent with previous studies, 4, 6, 7 we found that the M-receptor-mediated activation of I K,ACh is smaller in cAF than in SR patients. Moreover, reduced channel subunit expression at the mRNA and protein level corresponds well to the lower activation of I K,ACh in cAF. 6, 12, 13, 15 Nevertheless, we clearly demonstrated that I K,ACh becomes constitutively active when cAF develops. The selective I K,ACh blocker tertiapin concentration-dependently inhibited whole-cell CCh-activated I K,ACh , with higher potency in AF than in SR. Tertiapin blocks native I K,ACh channels with IC 50 values between 8 and 30 nmol/L 16, 19, 20 without significant effects on other ion channels. 19, 20 The effective concentration range of tertiapin found in the present study ( Figure 3 ) is in good agreement with the reported potency. In human atria, however, tertiapin unmasked a robust component of constitutively active I K,ACh in cAF and a substantially smaller one in SR. Recent findings in dog atria and pulmonary veins detected a tertiapin-sensitive current component contributing to basal inward rectifier current, and, consistent with our results, pacing-induced 
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Constitutively Active I K,ACh in AF tachycardia was associated with higher whole-cell current density of this current component. 16 Thus, the development of constitutively active I K,ACh currents in human cAF is probably a consequence of atrial remodeling contributing to the perpetuation rather than the initiation of the arrhythmia. The molecular basis of constitutively active I K,ACh is currently unknown. At the single-channel level, basal I K,ACh activity in cAF resulted from a higher number of channel openings and subsequent increase in channel open probability without concomitant changes in basic current properties. The basic properties of I K1 and I K,ACh were in good agreement with previous results. 24, 25 Thus, the reduced channel subunit expression in cAF 6, 12, 13, 15 is probably part of the modified I K,ACh regulation and can be interpreted as an adaptation on the higher frequency of I K,ACh openings in these patients.
The regulation of I K,ACh is complex, suggesting several putative mechanisms for constitutive activity of I K,ACh . Because the latter was not affected by blocking M-receptors with atropine, basal activity of I K,ACh is an agonist-independent process. Increased agonistindependent dissociation of G␣-and G␤␥-subunits of inhibitory G proteins appears unlikely because in dog atrial myocytes neither pertussis toxin treatment nor absence of GTP affected the tertiapin-sensitive component of basal current. 16 Evidence for constitutive activity of atrial I K,ACh channels was provided by earlier studies 26, 27 that showed that agonist-independent activation of I K,ACh requires ATP. Interestingly, consistent with the results from atria of dogs with tachypacing, 16 pertussis toxin treatment failed to prevent the ATP activation of I K,ACh . 26 Because activation of I K,ACh requires ATP, 26 -28 modified phosphorylationdependent channel regulation may contribute to the development of constitutively active I K,ACh in cAF. Consistent with this idea, recent publications have shown that in atrial myocardium Kir3.1 forms a macromolecular complex, allowing for local regulation of I K,ACh function. 28, 29 The atrial GIRK1 macromolecular complex is composed of the catalytic subunits of PKA, PKC, and CaMKII and the protein phosphatases PP1 and PP2A. 28, 29 Thus, the qualitative and quantitative composition of the GIRK1 macromolecular complex may change during AF, resulting in abnormal regulation of I K,ACh . Further work is needed to verify these hypotheses.
Study Limitations
In the present investigation we studied regulation of I K1 and I K,ACh only in isolated myocytes in vitro. The situation in multicellular preparations and in vivo is more complex. Thus, our data should be extrapolated with caution to the in situ atria. It is well known that the atria are heterogeneous tissues. Therefore, our data obtained in right atrial appendages may not necessarily reflect alterations in the rest of the atria. Digitalis, diuretics, and lipid-lowering drugs were more frequently prescribed in cAF. Thus, we cannot exclude that drugs affect density of I K1 and I K,ACh . Finally, our current recordings were performed at room temperature only. Their regulation may differ at physiological temperature.
Potential Clinical Implications
Our results show that the molecular basis for the higher amplitude of basal inward rectifier current in AF involves increased Kir2.x channel subunit expression 6, 15 and channel open probability (present study). Two-dimensional computer simulations of human atrial tissue showed that I K1 affects spiral wave dynamics. 30 An increase of I K1 during cAF resulted in reduced APD and hyperpolarization of the resting membrane potential, which is consistent with the shorter APD and the more negative resting membrane potential of multicellular trabeculae from patients with cAF. 6 The changes in APD and resting membrane potential were associated with higher availability of the Na ϩ current (I Na ) and enhanced excitability, leading to faster rotation frequencies and stabilization of functional reentry. Most important, reduction of I K1 in the model was associated with APD prolongation and depolarization, resulting in decreased rotation frequency and spiral wave termination. 30 Consistent with these findings, mice with overexpression of the I K1 channel subunit Kir2.1 31 and humans with a gain-of-function mutation of this channel develop cAF. 32 Thus, blockade of I K1 may be a viable antiarrhythmic option.
In analogy to I K1 , constitutively active I K,ACh may contribute to stabilization of functional reentry because in ACh-induced AF in sheep, the higher activation frequencies in left atria are associated with larger density of I K,ACh . 33 In vivo, vagal nerve stimulation abbreviates APD and increases APD heterogeneity and atrial vulnerability to tachyarrhythmia, 34 which perpetuate AF. 9 In knockout mice lacking the Kir3.4 channel subunit of I K,ACh , M-receptor stimulation did not induce AF, 11 suggesting that the effects of vagal nerve activation are mediated by I K,ACh . Thus, the agonist-independent constitutive activation of I K,ACh during cAF is expected to increase atrial vulnerability to tachyarrhythmia and to sustain AF. Because some antiarrhythmic drugs such as amiodarone, flecainide, quinidine, and verapamil, which effectively terminate AF, 35 are also inhibitors of I K,ACh , 36 -38 it cannot be excluded that their effectiveness in AF results in part from blockade of I K,ACh and that at least in some patients with AF the inhibition of constitutively active I K,ACh may have an antiarrhythmic affect.
Finally, there is evidence of circulating M 2 autoantibodies in AF patients, which may exert a tonic activation of M-receptor signal transduction. 39 Furthermore, the ACh concentrations in the synaptic clefts could be elevated because of reduced activity of its degrading enzyme acetylcholine esterase. 40 Because atropine had no effect on basal current in cAF, the development of constitutively active I K,ACh channels occurs in a receptor-independent manner. Thus, it is likely that the elevated synaptic ACh concentrations and the presence of M 2 autoantibodies and constitutively active I K,ACh channels reinforce each other in promoting AF. Further studies are needed to test these hypotheses.
